Tags

Type your tag names separated by a space and hit enter

Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis.
J Int Med Res. 2017 Apr; 45(2):383-398.JI

Abstract

Objective This meta-analysis aimed to investigate the efficacy and safety of pentoxifylline (PTF) plus angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) for proteinuria and kidney function in chronic kidney disease (CKD). Methods CENTRAL, EMBASE, Ovid-MEDLINE, PubMed, and CNKI were searched for relevant, randomized, controlled trials (RCTs). A meta-analysis was performed to review the effect of PTF plus ACEIs/ARBs vs. ACEIs/ARBs alone on proteinuria and kidney function in CKD. Results Eleven RCTs including 705 patients were retrieved. PTF plus ACEI/ARB treatment significantly decreased proteinuria in patients with CKD within 6 months (standard mean difference [SMD] -0.52; 95% CI -0.90 to 0.15; I2 = 68%) and significantly attenuated a decrease in estimated glomerular filtration rate (eGFR) in patients with stages 3-5 CKD after 6 months of treatment (standard mean difference [SMD] 0.30; confidence limit [Cl] 95% CI 0.06 to 0.54; I2 = 0%). PTF plus ACEIs/ARBs for 9 to 12 months significantly reduced albuminuria in patients with CKD (SMD-0.30, 95% CI -0.57 to 0.03; I2 = 0%) and alleviated the decline in eGFR in patients with stages 3-5 CKD (SMD 0.51; 95% CI 0.06 to 0.96; I2 = 61%). Conclusion The combination of an ACEI or ARB and PTF has a protective effect in reducing proteinuria by ameliorating the decline in eGFR in patients with stages 3-5 CKD.

Links

PMC Free PDF
PMC Free Full Text
Publisher Full Text
journals.sagepub.com
journals.sagepub.com
journals.sagepub.com

Authors+Show Affiliations

Liu D
1 Department of Nephrology, the Air Force General Hospital, Chinese PLA. Beijing, 100142, China.
Wang LN
2 Department of Nephrology, Henan Province Hospital of Chinese Medicine, Zhengzhou, 450002, China.
Li HX
1 Department of Nephrology, the Air Force General Hospital, Chinese PLA. Beijing, 100142, China.
Huang P
3 Department of Cardiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Qu LB
3 Department of Cardiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Chen FY
3 Department of Cardiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.

MeSH

Angiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsDisease ProgressionDrug Therapy, CombinationGlomerular Filtration RateHumansPentoxifyllinePhosphodiesterase InhibitorsProteinuriaRandomized Controlled Trials as TopicRenal Insufficiency, Chronic

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

28415944

Citation

Liu, Dong, et al. "Pentoxifylline Plus ACEIs/ARBs for Proteinuria and Kidney Function in Chronic Kidney Disease: a Meta-analysis." The Journal of International Medical Research, vol. 45, no. 2, 2017, pp. 383-398.
Liu D, Wang LN, Li HX, et al. Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis. J Int Med Res. 2017;45(2):383-398.
Liu, D., Wang, L. N., Li, H. X., Huang, P., Qu, L. B., & Chen, F. Y. (2017). Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis. The Journal of International Medical Research, 45(2), 383-398. https://doi.org/10.1177/0300060516663094
Liu D, et al. Pentoxifylline Plus ACEIs/ARBs for Proteinuria and Kidney Function in Chronic Kidney Disease: a Meta-analysis. J Int Med Res. 2017;45(2):383-398. PubMed PMID: 28415944.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis. AU - Liu,Dong, AU - Wang,Li-Na, AU - Li,Hong-Xia, AU - Huang,Ping, AU - Qu,Liang-Bo, AU - Chen,Fei-Yan, Y1 - 2017/01/01/ PY - 2017/4/19/entrez PY - 2017/4/19/pubmed PY - 2017/8/15/medline KW - ACEI/ARB KW - Pentoxifylline KW - chronic kidney disease KW - meta-analysis SP - 383 EP - 398 JF - The Journal of international medical research JO - J Int Med Res VL - 45 IS - 2 N2 - Objective This meta-analysis aimed to investigate the efficacy and safety of pentoxifylline (PTF) plus angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) for proteinuria and kidney function in chronic kidney disease (CKD). Methods CENTRAL, EMBASE, Ovid-MEDLINE, PubMed, and CNKI were searched for relevant, randomized, controlled trials (RCTs). A meta-analysis was performed to review the effect of PTF plus ACEIs/ARBs vs. ACEIs/ARBs alone on proteinuria and kidney function in CKD. Results Eleven RCTs including 705 patients were retrieved. PTF plus ACEI/ARB treatment significantly decreased proteinuria in patients with CKD within 6 months (standard mean difference [SMD] -0.52; 95% CI -0.90 to 0.15; I2 = 68%) and significantly attenuated a decrease in estimated glomerular filtration rate (eGFR) in patients with stages 3-5 CKD after 6 months of treatment (standard mean difference [SMD] 0.30; confidence limit [Cl] 95% CI 0.06 to 0.54; I2 = 0%). PTF plus ACEIs/ARBs for 9 to 12 months significantly reduced albuminuria in patients with CKD (SMD-0.30, 95% CI -0.57 to 0.03; I2 = 0%) and alleviated the decline in eGFR in patients with stages 3-5 CKD (SMD 0.51; 95% CI 0.06 to 0.96; I2 = 61%). Conclusion The combination of an ACEI or ARB and PTF has a protective effect in reducing proteinuria by ameliorating the decline in eGFR in patients with stages 3-5 CKD. SN - 1473-2300 UR - https://www.unboundmedicine.com/medline/citation/28415944/Pentoxifylline_plus_ACEIs/ARBs_for_proteinuria_and_kidney_function_in_chronic_kidney_disease:_a_meta_analysis_ L2 - https://journals.sagepub.com/doi/10.1177/0300060516663094?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -